{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020615","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.094836+00:00","generated_at":"2026-06-05T12:08:14.616531+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fulcrum Therapeutics Q4 2023 net loss $24.8M; Phase 3 REACH data expected Q4 2024","bullets":["Net loss $24.8M in Q4 2023 (vs $26.1M); full-year net loss $97.3M (vs $109.9M).","Cash, equivalents, and marketable securities $236.2M; cash runway into 2026.","Phase 3 REACH trial for losmapimod in FSHD on track for topline data in Q4 2024 after enrolling 260 patients.","Phase 1b PIONEER trial for pociredir in SCD restarted; cohorts evaluating 12 mg and 20 mg daily doses."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020615","json":"https://secwatch.observer/filing/0000950170-24-020615.json","markdown":"https://secwatch.observer/filing/0000950170-24-020615.md","text":"https://secwatch.observer/filing/0000950170-24-020615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/0000950170-24-020615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/fulc-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:08:14.616531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"764301bcda993afd2ac18d63ebf85b7f09df0e40","claim":"Fulcrum Therapeutics, Inc. reported fourth quarter and full year of 2023 results: revenue $0.9 million, net income $(24.8) million.","evidence_excerpt":"offering completed in January 2023 of $117.3 million, partially offset by our net cash used in operating activities in 2023. • Collaboration Revenue: Collaboration revenue was $0.9 million for the fourth quarter of 2023 as compared to $0.7 million for the fourth quarter of 2022. The increase of $0.2 million was attributable to an increase in revenues under our","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/0000950170-24-020615-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year of 2023"},{"label":"Revenue","value":"$0.9 million"},{"label":"Net income","value":"$(24.8) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}